Email RIS file
Bookmark
Report an Issue

Measurement of total body calcium in osteoporotic patients treated with salmon calcitonin [electronic resource].

Published
Upton, N.Y. : Brookhaven National Laboratory, 1981.
Oak Ridge, Tenn. : Distributed by the Office of Scientific and Technical Information, U.S. Dept. of Energy.
Physical Description
Pages: 12 : digital, PDF file
Additional Creators
Brookhaven National Laboratory and United States. Department of Energy. Office of Scientific and Technical Information
Access Online

Availability

I Want It
I Want It

Finding items...

Restrictions on Access
Free-to-read Unrestricted online access
Summary
In the past, the evaluation of therapies for osteoporosis has been limited by the lack of a suitable quantitative end point. The introduction of the technique of in vivo total body neutron activation analysis (TBNAA) has made possible the precise and accurate measurement of total body calcium (TBCa). Since almost 99 percent of TBCa is in the skeleton, TBNAA gives a direct measurement of skeletal mass. Thus, changes in skeletal mass serve as an objective criterion in the evaluation of the efficacy of the therapy in osteoporosis. Studies performed at Brookhaven National Laboratory and elsewhere have reported the use of calcitonin (CT) in the treatment of primary osteoporosis and related conditions in a limited number of patients. The physiological effects of CT as an inhibitor of bone resorption has been the rationale of its use. The results of a randomized, controlled, 2 year therapeutical trial of CT in a group of postmenopausal osteoporotic women are presented in this report.
Report Numbers
E 1.99:bnl-29673
E 1.99: conf-8105102-1
conf-8105102-1
bnl-29673
Subject(s)
Other Subject(s)
Note
Published through SciTech Connect.
01/01/1981.
"bnl-29673"
" conf-8105102-1"
"DE81024369"
International symposium on osteoporosis, Jerusalem, Israel, 31 May 1981.
Cohn, S.H.; Thompson, K.; Zanzi, I.
Funding Information
AC02-76CH00016
View MARC record | catkey: 14794297